Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States
Mixed acinar neuroendocrine carcinoma of the pancreas (MANEC-P) is an extremely rare malignancy with a poor prognosis. However, epidemiological estimates of MANEC-P remain unknown. This study aimed to estimate and compare the incidence, prevalence, and cancer-specific survival (CSS) of MANEC-P in th...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/3/840 |
| _version_ | 1797624953290358784 |
|---|---|
| author | Amro M. Abdelrahman Jun Yin Roberto Alva-Ruiz Jennifer A. Yonkus Jennifer L. Leiting Isaac T. Lynch Alessandro Fogliati Nellie A. Campbell Danielle M. Carlson Lewis R. Roberts Gregory J. Gores Rory L. Smoot Rondell P. Graham Thorvardur R. Halfdanarson Mark J. Truty |
| author_facet | Amro M. Abdelrahman Jun Yin Roberto Alva-Ruiz Jennifer A. Yonkus Jennifer L. Leiting Isaac T. Lynch Alessandro Fogliati Nellie A. Campbell Danielle M. Carlson Lewis R. Roberts Gregory J. Gores Rory L. Smoot Rondell P. Graham Thorvardur R. Halfdanarson Mark J. Truty |
| author_sort | Amro M. Abdelrahman |
| collection | DOAJ |
| description | Mixed acinar neuroendocrine carcinoma of the pancreas (MANEC-P) is an extremely rare malignancy with a poor prognosis. However, epidemiological estimates of MANEC-P remain unknown. This study aimed to estimate and compare the incidence, prevalence, and cancer-specific survival (CSS) of MANEC-P in the United States (US). Patients with MANEC-P were identified through the Surveillance, Epidemiology, and End Results (SEER) and National Program of Cancer Registries databases between 2000–2017. The primary outcomes included age-adjusted incidence rate, limited-duration prevalence, and CSS. A total of 630 patients were identified for the incidence analysis and 149 for the prevalence and CSS analyses. The MANEC-P incidence rate was 0.011 per 100,000 individuals, which was the lowest among pancreatic cancer histologic subtypes. The incidence rate was significantly higher in men and Black races and peaked at 75–79 years of age. The incidence rate was the lowest in the midwestern region (0.009) and the highest in the northeastern US (0.013). The 17-year prevalence was 0.00005%, indicating that 189 patients were alive in the United States at the beginning of 2018. The median CSS of MANEC-P was estimated to be 41 (23, 69) months. In conclusion, MANEC-P is very rare, and its incidence rate has been steady in the US over the last two decades. MANEC-P has a poor prognosis and is the 5th leading cause of pancreatic cancer-related death in the US. |
| first_indexed | 2024-03-11T09:49:57Z |
| format | Article |
| id | doaj.art-3f8332a3d41c4fbaa4d6634738c0e703 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T09:49:57Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3f8332a3d41c4fbaa4d6634738c0e7032023-11-16T16:17:58ZengMDPI AGCancers2072-66942023-01-0115384010.3390/cancers15030840Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United StatesAmro M. Abdelrahman0Jun Yin1Roberto Alva-Ruiz2Jennifer A. Yonkus3Jennifer L. Leiting4Isaac T. Lynch5Alessandro Fogliati6Nellie A. Campbell7Danielle M. Carlson8Lewis R. Roberts9Gregory J. Gores10Rory L. Smoot11Rondell P. Graham12Thorvardur R. Halfdanarson13Mark J. Truty14Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USADivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USADivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USADivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USADivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USADivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USADivision of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USADivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN 55905, USAMixed acinar neuroendocrine carcinoma of the pancreas (MANEC-P) is an extremely rare malignancy with a poor prognosis. However, epidemiological estimates of MANEC-P remain unknown. This study aimed to estimate and compare the incidence, prevalence, and cancer-specific survival (CSS) of MANEC-P in the United States (US). Patients with MANEC-P were identified through the Surveillance, Epidemiology, and End Results (SEER) and National Program of Cancer Registries databases between 2000–2017. The primary outcomes included age-adjusted incidence rate, limited-duration prevalence, and CSS. A total of 630 patients were identified for the incidence analysis and 149 for the prevalence and CSS analyses. The MANEC-P incidence rate was 0.011 per 100,000 individuals, which was the lowest among pancreatic cancer histologic subtypes. The incidence rate was significantly higher in men and Black races and peaked at 75–79 years of age. The incidence rate was the lowest in the midwestern region (0.009) and the highest in the northeastern US (0.013). The 17-year prevalence was 0.00005%, indicating that 189 patients were alive in the United States at the beginning of 2018. The median CSS of MANEC-P was estimated to be 41 (23, 69) months. In conclusion, MANEC-P is very rare, and its incidence rate has been steady in the US over the last two decades. MANEC-P has a poor prognosis and is the 5th leading cause of pancreatic cancer-related death in the US.https://www.mdpi.com/2072-6694/15/3/840MANEC-Pepidemiologyrare cancersmixed carcinomacancer surveillance and screening |
| spellingShingle | Amro M. Abdelrahman Jun Yin Roberto Alva-Ruiz Jennifer A. Yonkus Jennifer L. Leiting Isaac T. Lynch Alessandro Fogliati Nellie A. Campbell Danielle M. Carlson Lewis R. Roberts Gregory J. Gores Rory L. Smoot Rondell P. Graham Thorvardur R. Halfdanarson Mark J. Truty Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States Cancers MANEC-P epidemiology rare cancers mixed carcinoma cancer surveillance and screening |
| title | Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States |
| title_full | Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States |
| title_fullStr | Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States |
| title_full_unstemmed | Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States |
| title_short | Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States |
| title_sort | mixed acinar neuroendocrine carcinoma of the pancreas comparative population based epidemiology of a rare and fatal malignancy in the united states |
| topic | MANEC-P epidemiology rare cancers mixed carcinoma cancer surveillance and screening |
| url | https://www.mdpi.com/2072-6694/15/3/840 |
| work_keys_str_mv | AT amromabdelrahman mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT junyin mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT robertoalvaruiz mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT jenniferayonkus mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT jenniferlleiting mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT isaactlynch mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT alessandrofogliati mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT nellieacampbell mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT daniellemcarlson mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT lewisrroberts mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT gregoryjgores mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT rorylsmoot mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT rondellpgraham mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT thorvardurrhalfdanarson mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates AT markjtruty mixedacinarneuroendocrinecarcinomaofthepancreascomparativepopulationbasedepidemiologyofarareandfatalmalignancyintheunitedstates |